Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.

doi:10.1136/jitc-2020-000733

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.

Journal for immunotherapy of cancer - 1 Jun 2020

Correale Pierpaolo, Saladino Rita Emilena, Giannarelli Diana, Giannicola Rocco, Agostino Rita, Staropoli Nicoletta, Strangio Alessandra, Del Giudice Teresa, Nardone Valerio, Altomonte Maria, Pastina Pierpaolo, Tini Paolo, Falzea Antonia Consuelo, Imbesi Natale, Arcati Valentina, Romeo Giuseppa, Caracciolo Daniele, Luce Amalia, Caraglia Michele, Giordano Antonio, Pirtoli Luigi, Necas Alois, Amler Evzen, Barbieri Vito, Tassone Pierfrancesco, Tagliaferri Pierosandro

Abstract excerpt

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue human leukocyte antigen (HLA) molecules. Nivolumab is currently an active but expensive therapeutic agent for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Germ-Line Mutation

Share to HLA Antigens

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 32554614
DOI: 10.1136/jitc-2020-000733
PMCID: PMC7304840

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.PMID 32554614Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.Semantic proximity Read ↗

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.Semantic proximity Read ↗

Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.Semantic proximity Read ↗

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.Semantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.Semantic proximity Read ↗

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity Read ↗

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLCSemantic proximity Read ↗

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.